Pharmaceutical Companies' Role in State Vaccination Policymaking: The Case of Human Papillomavirus Vaccination
Pharmaceutical Companies' Role in State Vaccination Policymaking: The Case of Human Papillomavirus Vaccination
复制标题
DOI：
10.2105/ajph.2011.300576
复制
发表时间：
2012-05-01
影响因子：
12.7
通讯作者：
Colgrove, James
中科院分区：
文献类型：
--
作者：
Mello, Michelle M.;Abiola, Sara;Colgrove, James
目标.我们试图调查默克公司在国家人乳头瘤病毒（HPV）免疫政策制定中发挥的作用，以引起关键利益相关者对这些活动的适当性的看法，并探讨卫生政策制定者和行业之间关系的影响。我们使用了一系列国家案例研究，结合了对媒体报道和档案材料的分析，从关键线人访谈中获得的数据。我们采访了6个州的73名关键信息提供者，他们积极参与HPV疫苗政策的审议。默克公司通过充当信息资源、游说立法者、起草立法、动员女性立法者和医生组织、开展消费者营销活动以及填补疫苗获取方面的空白，促进了入学授权立法。立法者在很大程度上依赖默克公司的科学信息。大多数利益相关者认为疫苗制造商的游说原则上是可以接受的，但认为默克公司在这种情况下采取了过于激进和不透明的行动。尽管政策制定者承认制造商参与疫苗接种政策制定的效用，但过于激进、不完全透明或不脱离对立法者的财政贡献的行业游说可能会破坏促进新疫苗使用的立法前景。(Am J公共卫生。2012;102：893-898。doi：10.2105/AJPH.2011.300576）
Objectives. We sought to investigate roles that Merck & Co Inc played in state human papillomavirus (HPV) immunization policymaking, to elicit key stakeholders' perceptions of the appropriateness of these activities, and to explore implications for relationships between health policymakers and industry.Methods. We used a series of state case studies combining data from key informant interviews with analysis of media reports and archival materials. We interviewed 73 key informants in 6 states that were actively engaged in HPV vaccine policy deliberations.Results. Merck promoted school-entry mandate legislation by serving as an information resource, lobbying legislators, drafting legislation, mobilizing female legislators and physician organizations, conducting consumer marketing campaigns, and filling gaps in access to the vaccine. Legislators relied heavily on Merck for scientific information. Most stakeholders found lobbying by vaccine manufacturers acceptable in principle, but perceived that Merck had acted too aggressively and nontransparently in this case.Conclusions. Although policymakers acknowledge the utility of manufacturers' involvement in vaccination policymaking, industry lobbying that is overly aggressive, not fully transparent, or not divorced from financial contributions to lawmakers risks undermining the prospects for legislation to foster uptake of new vaccines. (Am J Public Health. 2012;102:893-898. doi:10.2105/AJPH.2011.300576)